The impact of transanal local excision of early rectal cancer on completion rectal resection without neoadjuvant chemoradiotherapy: a systematic review.
Abstract
[BACKGROUND] The impact of transanal local excision (TAE) of early rectal cancer (ERC) on subsequent completion rectal resection (CRR) for unfavorable histology or margin involvement is unclear. The aim of this study was to provide a comprehensive review of the literature on the impact of TAE on CRR in patients without neoadjuvant chemoradiotherapy (CRT).
[METHODS] We performed a systematic review of the literature up to March 2020. Medline and Cochrane libraries were searched for studies reporting outcomes of CRR after TAE for ERC. We excluded patients who had neoadjuvant CRT and endoscopic local excision. Surgical, functional, pathological and oncological outcomes were assessed. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were followed.
[RESULTS] Sixteen studies involving 353 patients were included. Pathology following TAE was as follows T0 = 2 (0.5%); T1 = 154 (44.7%); T2 = 142 (41.2%); T3 = 43 (12.5%); Tx = 3 (0.8%); T not reported = 9. Fifty-three percent were > T1. Abdominoperineal resection (APR) was performed in 80 (23.2%) patients. Postoperative major morbidity and mortality occurred in 22 (11.4%) and 3 (1.1%), patients, respectively. An incomplete mesorectal fascia resulting in defects of the mesorectum was reported in 30 (24.6%) cases. Thirteen (12%) patients developed recurrence: 8 (3.1%) local, 19 (7.3%) distant, 4 (1.5%) local and distant. The 5-year cancer-specific survival was 92%. Only 1 study assessed anal function reporting no continence disorders in 11 patients. In the meta-analysis, CRR after TAE showed an increased APR rate (OR 5.25; 95% CI 1.27-21.8; p 0.020) and incomplete mesorectum rate (OR 3.48; 95% CI 1.32-9.19; p 0.010) compared to primary total mesorectal excision (TME). Two case matched studies reported no difference in recurrence rate and disease free survival respectively.
[CONCLUSIONS] The data are incomplete and of low quality. There was a tendency towards an increased risk of APR and poor specimen quality. It is necessary to improve the accuracy of preoperative staging of malignant rectal tumors in patients scheduled for TAE.
[METHODS] We performed a systematic review of the literature up to March 2020. Medline and Cochrane libraries were searched for studies reporting outcomes of CRR after TAE for ERC. We excluded patients who had neoadjuvant CRT and endoscopic local excision. Surgical, functional, pathological and oncological outcomes were assessed. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were followed.
[RESULTS] Sixteen studies involving 353 patients were included. Pathology following TAE was as follows T0 = 2 (0.5%); T1 = 154 (44.7%); T2 = 142 (41.2%); T3 = 43 (12.5%); Tx = 3 (0.8%); T not reported = 9. Fifty-three percent were > T1. Abdominoperineal resection (APR) was performed in 80 (23.2%) patients. Postoperative major morbidity and mortality occurred in 22 (11.4%) and 3 (1.1%), patients, respectively. An incomplete mesorectal fascia resulting in defects of the mesorectum was reported in 30 (24.6%) cases. Thirteen (12%) patients developed recurrence: 8 (3.1%) local, 19 (7.3%) distant, 4 (1.5%) local and distant. The 5-year cancer-specific survival was 92%. Only 1 study assessed anal function reporting no continence disorders in 11 patients. In the meta-analysis, CRR after TAE showed an increased APR rate (OR 5.25; 95% CI 1.27-21.8; p 0.020) and incomplete mesorectum rate (OR 3.48; 95% CI 1.32-9.19; p 0.010) compared to primary total mesorectal excision (TME). Two case matched studies reported no difference in recurrence rate and disease free survival respectively.
[CONCLUSIONS] The data are incomplete and of low quality. There was a tendency towards an increased risk of APR and poor specimen quality. It is necessary to improve the accuracy of preoperative staging of malignant rectal tumors in patients scheduled for TAE.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 해부 | rectal
|
scispacy | 1 | ||
| 합병증 | anal
|
scispacy | 1 | ||
| 약물 | TAE
→ transanal local excision
|
scispacy | 1 | ||
| 약물 | TME
→ total mesorectal excision
|
C1273428
Total mesorectal excision
|
scispacy | 1 | |
| 약물 | [BACKGROUND]
|
scispacy | 1 | ||
| 약물 | ERC
→ early rectal cancer
|
scispacy | 1 | ||
| 약물 | CRR
→ completion rectal resection
|
scispacy | 1 | ||
| 약물 | CI 1.27
|
scispacy | 1 | ||
| 약물 | [CONCLUSIONS]
|
scispacy | 1 | ||
| 기법 | endoscopic
|
내시경 | dict | 1 | |
| 질환 | cancer
|
C0006826
Malignant Neoplasms
|
scispacy | 1 | |
| 질환 | continence disorders
|
scispacy | 1 | ||
| 질환 | tumors
|
C0027651
Neoplasms
|
scispacy | 1 | |
| 질환 | rectal cancer
|
scispacy | 1 | ||
| 질환 | Pathology
|
scispacy | 1 | ||
| 질환 | APR
→ Abdominoperineal resection
|
scispacy | 1 | ||
| 질환 | mesorectum
|
scispacy | 1 | ||
| 질환 | cancer-specific
|
scispacy | 1 | ||
| 질환 | malignant rectal tumors
|
scispacy | 1 | ||
| 기타 | patients
|
scispacy | 1 | ||
| 기타 | mesorectal fascia
|
scispacy | 1 | ||
| 기타 | APR
→ Abdominoperineal resection
|
scispacy | 1 |
MeSH Terms
Humans; Mesocolon; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Proctectomy; Rectal Neoplasms; Retrospective Studies; Treatment Outcome
📑 인용 관계
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Chemoradiotherapy and transanal endoscopic surgery versus transanal endoscopic surgery alone in T1N0M0 rectal cancer: a multicenter, randomized, controlled, phase III clinical trial (TAUTEM-T1 study).
- Endoscopic Assistance in Surgery for Insular Lesions: Anatomic Study and Clinical Application.
- Endoscopic disconnection of hypothalamic hamartoma: an already outdated story?
- Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery.
- Clinical Efficacy Analysis of Functional Rhinoplasty Assisted by Nasal Endoscopy.